A Study of ART105 in Healthy Adult Participants (NCT07748026) | Clinical Trial Compass
Not Yet RecruitingPhase 1
A Study of ART105 in Healthy Adult Participants
24 participantsStarted 2026-08-03
Plain-language summary
The goal of this clinical trial is to learn if ART105 is safe in healthy adult participants. It will also learn about the PK and PD profiles of ART105. The main questions it aims to answer are:
Is ART105 safe and tolerable in adult participants? How does the ART105 influence the urine PC1 level of participants?
Participants will:
recieve single dose of ART105 and visit the clinic 3 months
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Voluntary participation with signed written informed consent (ICF) .
. Male or female, aged 18-55 years (inclusive).
. males ≥ 50 kg; females ≥ 45 kg; and BMI between 19 and 26 kg/m² (inclusive).
. No history of clinically significant abnormalities.
. Normal or not clinically significant (NCS) findings at screening for vital signs, physical exam, lab tests, 12-lead ECG, and abdominal ultrasound.
. Participants of childbearing potential (or males with partners of childbearing potential) must agree to use highly effective contraception.
Exclusion criteria
. Any uncontrolled or severe disease, or any medical or surgical condition that may interfere with the participant's participation in the clinical trial
. History of hypersensitivity to oligonucleotide drugs, or known hypersensitivity to the investigational product or any of its excipients
. Use of any ASO or siRNA drugs within 12 months prior to the first dose
. History of alcohol abuse
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. History of drug or substance abuse, or a positive urine drug abuse screening test
. Major surgery within 3 months prior to the administration of the investigational product or planned elective surgery during the study period.
. Use of any prescription medications, over-the-counter (OTC) drugs, or herbal medicines within 14 days prior to the administration of the investigational product, or within 5 half-lives of the drug (whichever is longer).
. Enrollment in or ongoing participation in any other clinical trial within 3 months or 5 half-lives (whichever is longer) prior to the administration of the investigational product